Clinical effectiveness of hypertonic sodium lactate infusion for intraoperative brain relaxation in patients undergoing scheduled craniotomy for supratentorial brain tumor resection: A study protocol of a single center double-blind randomized controlled phase II pilot trial

Guillaume Besch, Anne-Laure Parmentier, Francis Berthier, Hélène Jaeg, Julien Villeneuve, Fethi Hammoudi, Nans Scaringella, Anne-Laure Clairet, Lucie Vettoretti, Gilles Chopard, Laurent Thines, David Ferreira, Emmanuel Samain, Sebastien Pili-Floury, Guillaume Besch, Anne-Laure Parmentier, Francis Berthier, Hélène Jaeg, Julien Villeneuve, Fethi Hammoudi, Nans Scaringella, Anne-Laure Clairet, Lucie Vettoretti, Gilles Chopard, Laurent Thines, David Ferreira, Emmanuel Samain, Sebastien Pili-Floury

Abstract

Introduction: Hyperosmolar solutions are prescribed in neurosurgery patients to provide satisfactory intraoperative brain relaxation and to lower cerebral injuries related to surgical retractors. Mannitol is traditionally considered as the first-choice solution for brain relaxation in neurosurgery patients. Hypertonic sodium lactate infusion was reported to provide a higher and longer osmotic effect compared to mannitol in severely brain-injured patients and to prevent impaired cerebral energetics related to brain injuries. To date, the clinical effectiveness of hypertonic sodium lactate infusion has never been studied in neurosurgery patients. The hypothesis of the study is that hyperosmolar sodium lactate infusion may provide satisfactory intraoperative brain relaxation in patients undergoing scheduled craniotomy for supratentorial brain tumor resection.

Methods and analysis: We designed a phase II randomized, controlled, double-blind, single-center pilot trial, and aim to include 50 adult patients scheduled for craniotomy for supratentorial brain tumor resection under general anesthesia. Patients will be randomized to receive either mannitol (conventional group) or hypertonic sodium lactate (intervention group) infusion at the time of skin incision. Brain relaxation (primary outcome) will be assessed immediately after opening the dura by the neurosurgeon blinded to the treatment allocated using a validated 4-point scale. The primary outcome is the proportion of satisfactory brain relaxation, defined as brain relaxation score of 3 or 4.

Ethics and dissemination: This study was approved by the Ethics Committee (Comité de Protection des Personnes Est III) and authorized by the French Health Authority (Agence Nationale de Sécurité des Médicaments, Saint-Denis, France). The University Hospital of Besancon is the trial sponsor and the holder of all data and publication rights. Results of the study will be submitted for publication in a peer-review international medical journal and for presentation in abstract (oral or poster) in international peer-reviewed congresses.

Registration: The trial is registered with ClinicalTrials.gov (Identifier: NCT04488874, principal investigator: Prof Guillaume Besch, date of registration: July 28, 2020).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

References

    1. Li J, Gelb AW, Flexman AM, et al. . Definition, evaluation, and management of brain relaxation during craniotomy. Br J Anaesth. 2016;116:759–69.
    1. Gruenbaum SE, Meng L, Bilotta F. Recent trends in the anesthetic management of craniotomy for supratentorial tumor resection. Curr Opin Anaesthesiol. 2016;29:552–7.
    1. Rosenørn J. Self-retaining brain retractor pressure during intracranial procedures. Acta Neurochir (Wien). 1987;85:17–22.
    1. Zhong J, Dujovny M, Perlin AR, et al. . Brain retraction injury. Neurol Res. 2003;25:831–8.
    1. Francony G, Fauvage B, Falcon D, et al. . Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med. 2008;36:795–800.
    1. Mendelow AD, Teasdale GM, Russell T, et al. . Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury. J Neurosurg. 1985;63:43–8.
    1. Paczynski R. Osmotherapy. Basic concepts and controversies. Crit Care Clin. 1997;13:105–29.
    1. Seo H, Kim E, Jung H, et al. . A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017;126:1839–46.
    1. Marik PE, Varon J, Trask T. Management of head trauma. Chest. 2002;122:699–711.
    1. McManus ML, Soriano SG. Rebound swelling of astroglial cells exposed to hypertonic mannitol. Anesthesiology. 1998;88:1586–91.
    1. Ichai C, Armando G, Orban JC, et al. . Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med. 2009;35:471–9.
    1. Ichai C, Payen JF, Orban JC, et al. . Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial. Intensive Care Med. 2013;39:1413–22.
    1. Kahle KT, Staley KJ, Nahed BV, et al. . Roles of the cation-chloride cotransporters in neurological disease. Nat Clin Pract Neurol. 2008;4:490–503.
    1. Chen H, Sun D. The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res. 2005;27:280–6.
    1. Bouzat P, Magistretti PJ, Oddo M. Hypertonic lactate and the injured brain: facts and the potential for positive clinical implications. Intensive Care Med. 2014;40:920–1.
    1. Bouzat P, Sala N, Suys T, et al. . Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014;40:412–21.
    1. Quintard H, Patet C, Zerlauth JB, et al. . Improvement of neuroenergetics by hypertonic lactate therapy in patients with traumatic brain injury is dependent on baseline cerebral lactate/pyruvate ratio. J Neurotrauma. 2016;33:681–7.
    1. Berthet C, Lei H, Thevenet J, et al. . Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab. 2009;29:1780–9.
    1. Berthet C, Castillo X, Magistretti PJ, et al. . New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration. Cerebrovasc Dis. 2012;34:329–35.
    1. Chan AW, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.
    1. Todd MM, Warner DS, Sokoll MD, et al. . A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology. 1993;78:1005–20.
    1. Toulouse E, Masseguin C, Lafont B, et al. . French legal approach to clinical research. Anaesth Crit Care Pain Med. 2018;37:607–14.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi